PMID- 11716174
OWN - NLM
STAT- MEDLINE
DCOM- 20020312
LR  - 20190822
IS  - 0903-1936 (Print)
IS  - 0903-1936 (Linking)
VI  - 18
IP  - 4
DP  - 2001 Oct
TI  - Major histocompatibility locus genetic markers of beryllium sensitization and 
      disease.
PG  - 677-84
AB  - Hypersensitivity to beryllium (Be) is found in 1-16% of exposed workers 
      undergoing immunological screening for beryllium disease using the beryllium 
      lymphocyte proliferation test (BeLPT). However, only approximately 50% of 
      BeLPT-positive workers present with lung granulomas (i.e. berylliosis). As 
      berylliosis is associated with the human leukocyte antigen (HLA)-DP supratypic 
      marker DPGlu69, the authors asked whether this marker is differentially 
      associated with disease presentation. A population of 639 workers from a 
      beryllium factory undergoing BeLPT screening was evaluated in a nested 
      case-control study for the prevalence of HLA-DPGlu69, the HLA-DPB1, HLA-DQ and 
      HLA-DR alleles and of the biallelic tumour necrosis factor (TNF)-alpha 
      polymorphism TNF-alpha-308 in 23 individuals presenting as "sensitized" (i.e. 
      BeLPT-positive without lung granulomas) and in 22 presenting as "diseased" (i.e. 
      BeLPT-positive with granulomas in the lung biopsy). The HLA-DPGlu69 marker was 
      associated with "disease" (odds ratio (OR) 3.7, p=0.016, 95% confidence interval 
      (CI) 1.4-10.0), whilst the high TNF-alpha production-related TNF-alpha-308*2 
      marker was associated with both a positive BeLPT (OR 7.8, corrected p<0.0001, 95% 
      CI 3.2-19.1) with no difference between "sensitization" and "disease". 
      Furthermore, the HLA-DRArg74 marker was associated with "sensitization" without 
      disease (OR 3.96, p=0.005, 95%, CI 1.5-10.1). The data indicate that tumour 
      necrosis factor-alpha, human leukocyte antigen-DR and human leukocyte antigen-DP 
      markers play different roles in beryllium sensitization and granuloma formation 
      in beryllium-exposed workers.
FAU - Saltini, C
AU  - Saltini C
AD  - Division of Respiratory Diseases of the University of Rome Tor Vergata at the 
      National Institute for Infectious Diseases, Spallanzani Hospital, Rome, Italy.
FAU - Richeldi, L
AU  - Richeldi L
FAU - Losi, M
AU  - Losi M
FAU - Amicosante, M
AU  - Amicosante M
FAU - Voorter, C
AU  - Voorter C
FAU - van den Berg-Loonen, E
AU  - van den Berg-Loonen E
FAU - Dweik, R A
AU  - Dweik RA
FAU - Wiedemann, H P
AU  - Wiedemann HP
FAU - Deubner, D C
AU  - Deubner DC
FAU - Tinelli, C
AU  - Tinelli C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
RN  - 0 (Genetic Markers)
RN  - 0 (HLA-DP Antigens)
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - OW5102UV6N (Beryllium)
SB  - IM
MH  - Adult
MH  - Berylliosis/*genetics/immunology/pathology
MH  - Beryllium/*adverse effects/immunology
MH  - Case-Control Studies
MH  - Female
MH  - Gene Frequency
MH  - Genetic Markers
MH  - Genetic Predisposition to Disease
MH  - HLA-DP Antigens/genetics
MH  - HLA-DQ Antigens/genetics
MH  - HLA-DQ beta-Chains
MH  - HLA-DR Antigens/genetics
MH  - Humans
MH  - Hypersensitivity/etiology/*genetics
MH  - Lung/pathology
MH  - Lymphocyte Activation
MH  - Major Histocompatibility Complex/*genetics
MH  - Male
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Genetic
MH  - Tumor Necrosis Factor-alpha/genetics
EDAT- 2001/11/22 10:00
MHDA- 2002/03/13 10:01
CRDT- 2001/11/22 10:00
PHST- 2001/11/22 10:00 [pubmed]
PHST- 2002/03/13 10:01 [medline]
PHST- 2001/11/22 10:00 [entrez]
AID - 10.1183/09031936.01.00106201 [doi]
PST - ppublish
SO  - Eur Respir J. 2001 Oct;18(4):677-84. doi: 10.1183/09031936.01.00106201.